⌘K
Technocrats Plasma Systems operates in the Machine Tools — Metal-Cutting And Welding Equipment Manufacturing industry, demonstrating exceptional financial growth and strong market sentiment for its SME IPO.
Deterministic verdict 'Avoid': listing=83/Strong Apply, short=72/Neutral Positive, long=71/Apply; overall=68.8; confidence=100.0/100 | computed financials: fin=84, growth=100, D/E=0.38 (70% math / 30% model) | market signals: alignment=n/a (OFS None%), anchor quality=30 (marquee 0.0%), GMP trend=rising, overhang=80 (-4.0 pts short-term) | demand profile: reservation weights QIB/NII/Ret 29%/21%/50%, QIB effective demand=48.35x, institutional contribution=24%, breadth=0.97 | unlocks: anchor unlock ~14.2% of issue at T+30d, ~14.2% at T+90d | red flags: R1_governance (severe governance concern in critical risks); R10_data_conflict (conflicting source data: roe_pct (investorgain=56.1 vs drhp_computed=38.3)) | rule: severe governance concern in critical risks. | Analyst notes: The 'Strong Apply' verdict is driven by the company's exceptional financial growth, very strong return ratios, and a highly attractive valuation relative to its peers. The overwhelming positive market sentiment, reflected in high subscription rates and GMP, further supports this recommendation. While significant governance and litigation risks are present, the compelling financial performance and valuation provide a strong margin of safety and potential for substantial returns, particularly in the short term and on listing.
Listing-day performance is not available yet. It will appear here once this IPO has listed and results are recorded.
| Category | Shares Offered | % of Issue | Share |
|---|---|---|---|
| QIB | 21,91,000 | 47.42% | |
| NII (HNI) | 6,60,000 | 14.29% | |
| Retail | 15,38,000 | 33.29% | |
| Market Maker | 2,31,000 | 5% |
| Investor | |||
|---|---|---|---|
| FORTUNE HANDS GROWTH FUND-FORTUNE HANDS GROWTH FUND SCHEME I | 2,28,000 | ₹3.01 Cr | 17.35% |
| PI SQUARE INDIA EMERGING BUSINESS INVESTMENT FUND | 2,02,000 | ₹2.67 Cr | 15.37% |
| M7 GLOBAL FUND PCC-CELL DEWCAP FUND | 2,01,000 | ₹2.65 Cr | 15.3% |
| PESB ALPHA FUND | 1,52,000 | ₹2.01 Cr | 11.57% |
| VBCUBE VENTURES FUND II | 1,33,000 | ₹1.76 Cr | 10.12% |
| KHANDELWAL FINANCE PVT.LTD. | 1,25,000 | ₹1.65 Cr | 9.51% |
| VBCUBE VENTURES FUND | 1,21,000 | ₹1.6 Cr | 9.21% |
| EVERGROW CAPITAL OPPORTUNITIES FUND | 76,000 | ₹1 Cr | 5.78% |
| ARNESTA GLOBAL OPPORTUNITIES FUND PCC-ARNESTA GLOBAL FUND 1 | 76,000 | ₹1 Cr | 5.78% |
Premium gain of 32.58% over issue price.
Exceptional revenue and profit growth (CAGR 354% and 159% respectively over two years).
Very strong return ratios (ROE 56.1%, ROCE 48.55%, RoNW 56.1%).
Highly attractive post-IPO valuation (P/E 15.47x, P/B 1.52x) compared to peers.
Low debt-to-equity ratio (0.38).
High promoter holding post-IPO (64.0%).
Overwhelmingly positive market sentiment (203.36x overall subscription, 32.58% GMP premium).
Operating in a growing industry.
Strong industry tailwinds, successful expansion, new product innovation, improved operational efficiency.
Consistent market demand, stable raw material prices, effective execution of current strategies.
Intense competition, economic slowdown, adverse regulatory changes, failure to manage identified risks.
Exceptional subscription rates across all categories (203.36x overall) and a significant GMP of 32.58% indicate very strong demand and high likelihood of substantial listing gains.
The attractive post-IPO valuation relative to peers, coupled with robust financial performance and strong market sentiment, suggests significant upside potential in the short term.
While the company demonstrates impressive historical growth and strong return ratios in a growing industry, the identified governance issues, litigation risks, and lack of detailed business strategy temper the long-term conviction. However, the attractive valuation provides a margin of safety.
Final verdict: Avoid (confidence High).
Positive: Exceptional revenue and profit growth.
Red flag: severe governance concern in critical risks
Advisory: conflicting source data: roe_pct (investorgain=56.1 vs drhp_computed=38.3)
Listing-gain vs long-term: Strong Apply / Apply.